Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Diagnosis: MelanomaNCT ID: NCT01375842
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-314
This Phase I, multicenter, first in human, open-label, dose escalation study will evaluate the safety, tolerability, and pharmacokinetics of Atezolizumab administered as single agent by intravenous (IV) infusion to patients with locally advanced or metastatic solid malignancies or hematologic malignancies.
Conducting Institutions: Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital
Overall PI: Frank Stephen Hodi, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Daniel Cho, MD,
Beth Israel Deaconess Medical CenterDonald Lawrence, MD,
Massachusetts General Hospital
Contacts: Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Dana-Farber Cancer Institute:
firstname.lastname@example.orgMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100